Is Proteome Sciences plc’s Fuel Running Low? The Stock Just Declined Again

 Is Proteome Sciences plc's Fuel Running Low? The Stock Just Declined Again

The stock of Proteome Sciences plc (LON:PRM) is a huge mover today! The stock decreased 36.22% or GBX 3.18 on October 31, hitting GBX 5.6. About 12.79M shares traded hands or 4968.90% up from the average. Proteome Sciences plc (LON:PRM) has declined 64.42% since April 1, 2016 and is downtrending. It has underperformed by 67.90% the S&P500.
The move comes after 8 months negative chart setup for the GBX 12.77 million company. It was reported on Oct, 31 by Barchart.com. We have GBX 4.98 PT which if reached, will make LON:PRM worth GBX 1.40M less.

More important recent Proteome Sciences plc (LON:PRM) news were published by: Uk.Finance.Yahoo.com which released: “Proteome Sciences plc (PRM.L)” on March 29, 2014, also Fool.Co.Uk published article titled: “Are Nanoco Group PLC, Proteome Sciences plc And Vislink plc Heading For The …”, Fool.Co.Uk published: “Do Today’s Updates Make DX (Group) PLC, British Polythene Industries plc And …” on February 29, 2016. More interesting news about Proteome Sciences plc (LON:PRM) was released by: Businesswire.com and their article: “Industry-Academic Collaboration Targets Major Proteomics Quantitation Advances” with publication date: March 19, 2014.

Proteome Sciences plc is a protein biomarker firm specializing in proteomics and peptidomics services and applications, and mass spectrometry protein analysis. The company has a market cap of 12.77 million GBP. The Firm is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It currently has negative earnings. It operates through the EU (the United Kingdom and Germany) and the United States geographic regions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment